Navigation Links
PeloBiotech to Distribute ReachBio’s Products in Germany, Austria and Switzerland
Date:10/28/2013

Seattle, WA (PRWEB) October 28, 2013

ReachBio LLC (Seattle, WA, USA) announced today that it has signed an agreement with PeloBiotech GmbH (Munich, Germany) giving PeloBiotech exclusive distribution rights to ReachBio’s full product line for the life science research market within Germany, Austria and Switzerland.

ReachBio provides research products and contract services for applications in basic life science research, drug research & development and toxicology. The company’s main product lines consist of ColonyGel™ methylcellulose-based media for hematopoietic colony-forming cell (CFC) assays and cryopreserved normal human primary cells isolated from blood, cord blood and bone marrow.

The extensive ColonyGel™ semi-solid media product line includes multiple formulations with different cytokine (growth factor) combinations optimized for the growth of the different progenitor cells in blood and bone marrow. In the cytokine-optimized, semi-solid environment provided by ColonyGel™, the different progenitors grow as morphologically distinct three-dimensional colonies that can be identified and scored microscopically. The ColonyGel™ line-up also includes formulations optimized for different species, including human, mouse, rat, dog and non-human primate. Applications of CFC assays using ColonyGel™ media include research into normal and abnormal hematological development, leukemia and cancer stem cells, cell therapy, stem cell biology, investigative toxicology, etc.

ReachBio’s line of normal primary human cells include highly purified cell types from blood such as the various subsets of T lymphocytes, B lymphocytes, natural killer cells and monocytes. It also includes “ReachBio Qualified” CD34+ and CD133+ stem cells/primitive progenitors purified from cord blood and bone marrow that have been pre-qualified in CFC assays. ReachBio also specializes in providing customized cell isolation services for customers with specific needs such as unique cell types, particular donor background or HLA type, repeat donor cell isolations, and/or customized vial sizes.

“ReachBio is extremely happy to have PeloBiotech representing our products in Germany, Austria and Switzerland,” said Rob Chaney, ReachBio’s General Manager and COO. “We have known Peter Frost, one of the founders of PeloBiotech, for many years and have the utmost respect for him and his knowledge of the life science research market within these research intensive countries. He has already been aiding ReachBio’s sales and business development efforts for our specialized cell biology contract research services in this same territory for the last few years with great results. So having him and PeloBiotech now representing our products as well is a great fit and makes perfect sense.”

Said Dr. Peter Frost, CEO of PeloBiotech, “We are delighted to now be distributing ReachBio’s ColonyGel™ and normal human cell products. The high quality of these products reflects the reputation for quality and value that ReachBio has built regarding both its contract research services and its products. ColonyGel™ provides researchers performing CFC assays a great alternative to the methylcellulose-based media provided by the leading competitor, which has become quite overpriced through many years of price increases. Additionally, we are happy that ReachBio is able to provide not only standard vials of high quality cryopreserved human cells but also flexible customized offerings. This is a great advantage to pharma companies that often have unique requirements for specific types of cells and a strong need for vial-to-vial and lot-to-lot reproducibility. This fits in very well with PeloBiotech’s goal to provide customized solutions to aid our customers’ research.”

About ReachBio LLC
ReachBio LLC is a life sciences organization based in Seattle, WA. It provides specialized contract research services and products to biopharmaceutical, biotechnology, and related organizations worldwide.

About PeloBiotech GmbH
PeloBiotech GmbH is based in Martinsried (near Munich), Germany and is a local distributor of high quality life science research tools and reagents with a focus on primary cell and stem cell biology, 3D cell culture and media development for human primary cells.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11272201.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Adimarket, Inc. Reaches Agreement with Equipmed to Promote and Distribute DermaPen Throughout Latin America and the Caribbean
2. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
3. First Bedside DNA Test to be Distributed by Chirus in UK
4. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
5. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
6. ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits
7. Fleur de Lis Hydroponics Releases New Line of Hydroponic Products
8. The Future of Brazil Tobacco and Tobacco Products Packaging to 2017
9. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
10. BioConvergence® Presents Case Study on Temperature Controlled Pharmaceutical Products
11. Intrexon Establishes "Living Arts" Company, BioPop, to Create Consumer Products Inspired by Nature and Made Possible through Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... YORK , March 27, 2017 ... developing novel therapies for neurodegenerative diseases, including Alzheimer,s ... that its application to list the Company,s common ... approved by The NASDAQ Stock Market, a unit ... the listing, Neurotrope will ring the Opening Bell at ...
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider ... that its board of directors has amended its shareholder rights plan. The ... 2017 to March 27, 2018. The amendment was not in response to ... ... Ltd. is a China -based biopharmaceutical company that ...
(Date:3/24/2017)... VILLAGE, Calif. , March 24, 2017   ... dermatology and aesthetics company, today announced that Richard ... Officer, effective March 24.   Peterson, who brings ... succeed John Smither , who is retiring at ... Sienna in an advisory capacity. Peterson joins Sienna from ...
Breaking Biology Technology:
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):